ECM
CPRX

Evergreen Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Evergreen Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$428K Buy
13,630
+88
+0.6% +$2.6K 0.01% 1002
2026
Q1 		$335K Buy
+13,542
New +$323K 0.01% 1042

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Evergreen Capital Management's CPRX Position: Q2 2026 in Review

Evergreen Capital Management increased its Catalyst Pharmaceutical (CPRX) stake by 0.65% in Q2 2026, buying an estimated $2.6K and bringing the position to 13,630 shares worth $428K. The position accounts for 0.01% of the portfolio, ranked #1002.

Evergreen Capital Management first reported a position in CPRX in Q1 2026 and has held it in 2 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Evergreen Capital Management held 13,630 shares of Catalyst Pharmaceutical worth $428K as of Q2 2026.
  • Evergreen Capital Management bought 88 Catalyst Pharmaceutical shares in Q2 2026, an estimated $2.6K.
  • Catalyst Pharmaceutical made up 0.01% of Evergreen Capital Management's portfolio in Q2 2026, its #1002 holding.
  • Evergreen Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2026 and has held it in 2 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Evergreen Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.